悠洋棋牌

發布時間:2017-02-27         浏覽次數:5355

悠洋棋牌, 教授

國家傳染病診斷試劑與疫苗工程技術研究中心(NIDVD),分子疫苗學與分子診斷學國家重點實驗室(SKLVD),病毒性肝炎研究組組長

聯系電話:0592-2880627

E-Mail: yuanquan@xmu.edu.cn


主要學習經曆:

2001-2005, 廈門大學, 生物科學, 理學學士

2005-2012, 廈門大學, 生物化學與分子生物學, 理學博士

科研工作經曆:

2009-至今, 廈門大學NIDVD, 病毒性肝炎研究組, 組長

2012-2015, 廈門大學公共卫生学院, 助理教授
2016-至今, 廈門大學公共卫生学院教授

現階段主要研究興趣:

1.乙型肝炎病毒治療新藥物的發展及轉化醫學研究

2.新型治療性抗體發展及相關免疫學機制研究

3.乙型肝炎病毒免疫致病機制、分子流行特征與病毒進化規律研究

4.以精准醫療爲目標的新型診斷試劑發展及轉化醫學研究

5.肝髒病原相關細胞及動物模型研究

Selected publications:

1. Zhang TY?, Yuan Q?*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo LW, Cheng T, Chen YX, Tao MH, Shih, JWK, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*. Prolonged suppression of hepatitis B virus in mice by a novel antibody that targets a unique epitope on HBsAg. Gut. 2015 Sep 30. pii: gutjnl-2014-308964. (Co-Corresponding/Co-First author)

2. Song LW, Wang YB, Fang LL, Wu Y, Yang L, Chen JY, Ge SX, Zhang J, Xiong YZ, Deng XM, Min XP, Zhang J, Chen PJ, Yuan Q*, Xia NS*.Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. Anal Chem. 2015 May 19;87(10):5173-80. (*Co-Corresponding author)

3. Yuan Q?, Song LW?, Cavallone D, Moriconi F, Cherubini B, Colombatto P, Oliveri F, Coco BA, Ricco G, Bonino F, Shih JW, Xia NS, Brunetto MR. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. PLoS One. 2015 Jun 26;10(6):e0130209. (? Co-First Author)

4. Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015 Jan 1;5(3):218-26.

5. Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q*, Zhang J, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015 Feb;21(2):197-203. (*Co-Corresponding author)

6. Fan R?, Sun J?, Yuan Q?, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2015 Jan 13. pii: gutjnl-2014-308546. (? Co-First Author)

7. Yang H, Chen YZ, Zhang Y, Wang X, Zhao X, Godfroy JI, Liang Q, Zhang M, Zhang T, Yuan Q, Ann Royal M, Driscoll M, Xia NS, Yin H, Xue D. A lysine-rich motif in the phosphatidylserine receptor PSR-1 mediates recognition and removal of apoptotic cells. Nat Commun. 2015 Jan 7;6:5717.

8. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J*, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013 Jan;62(1):182-4.

9. Huang CH?, Yuan Q?, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J, Xia NS. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012 Oct;57(4):720-9. (? Co-First Author)

10. Geng X, Huang C, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia NS*, Xue D*. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18471-6.

11. Wang SH, Yeh SH*, Lin WH, Yeh KH, Yuan Q, Xia NS, Chen DS, Chen PJ. Estrogen Receptor-α Represses Transcription of HBV Genes via Interaction with Hepatocyte Nuclear Factor 4α. Gastroenterology. 2012 Apr;142(4):989-998.e4

12. Yuan Q, Cheng XD, Yang BC, Zheng QB, Chen YX, Chen QR, Zeng F, Zhang R, Ge SX, Hao XK, Chen H, Zhang J, Xia NS*. Differential diagnosis of pandemic (H1N1) 2009 infection by detection of haemagglutinin with an enzyme-linked immunoassay. Clin Microbiol Infect. 2011 Oct;17(10):1574-80.

13. Yu H?, Yuan Q?, Ge SX, Wang HY, Zhang YL, et al. Yu H, Yuan Q, Ge SX, Wang HY, Zhang YL, Chen QR, Zhang J*, Chen PJ, Xia NS. PLoS One. 2010 Feb 19;5(2):e9297.(?Co-First Author)

14. Yuan Q?, Ou SH?, Chen CR*, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AE, Shih JW, Zhang J*, Xia NS. Molecular Characteristics of Occult Hepatitis B virus from Blood donors in the southeast China. J. Clin. Microbiol. Feb. 2010, p. 357–362. (? Co-First Author)

轉化應用:

1.乙型肝炎病毒核酸相關抗原檢測試劑盒.國食藥監械(准)字20103400614

2.乙型肝炎病毒核心抗體雙抗原夾心法檢測試劑盒.國食藥監械(准)字20103401232

3.乙型肝炎病毒表面抗原檢測試劑盒(HBsAg Ultra).國食藥監械(准)字20113400140, CE Marketed, No. 41 055/1 01 I 1 120'l2lCE

4.甲型H1N1流感病毒(2009HA抗原檢測試劑盒.國食藥監械(准)字20103400974

5.甲型流感病毒抗原檢測試劑盒.國食藥監械(准)字20093400979

6.丁型肝炎病毒IgG抗體檢測試劑.國食藥監械(准)字20123400893

7.丁型肝炎病毒IgM抗體檢測試劑.國食藥監械(准)字20123400895

專利:

1.聯合檢測HBVS1抗原和核心抗原的方法及診斷試劑盒. 中国发明专利授权號:ZL 200610090512.7. 中国香港专利授权號:WO2008003236 A1.

2.一種乙型肝炎病毒核心蛋白抗體定量檢測的方法及其在監控慢性乙型肝炎患者病情發展和預測治療療效中的用途. 发明专利公开號:CN103217533A,PCT公开號: WO2013107355 A1

3.用于治療HBV 感染及相關疾病的多肽及抗體. 发明专利公开號: CN 201310222728, PCT公开號: WO2013185558A1

4.一種可誘使顆粒化的多肽及其用途. 发明专利公开號:CN102816216 A

研究課題(部分):

1.抗体对慢性病毒性感染的治疗作用和机制研究,福建省傑出青年基金项目,2015.01-2017.12,課題主持人。

2.隱匿性乙型肝炎病毒感染分子機制的細胞及動物模型驗證研究 (81371819) ,國家自然科學基金面上項目,2014.01-2017.12,課題主持人。

3.慢性乙型肝炎治療新標識:乙型肝炎病毒核心抗體的臨床意義及免疫機制(81261160322),國家自然科學基金國際(地區)合作與交流項目,2013.01 – 2015.12,主要研究者。

4.基于單克隆抗體的乙肝表面抗原清除新方法研究(2013ZX10002002 -001-001),艾滋病和病毒性肝炎等重大傳染病防治科技重大專項子課題,2013.01-2015.12,主要研究者。

5.中國隱匿性乙型肝炎病毒感染的分子病毒學研究(2009J06020),福建省自然科學基金,2009.03-2012.03(已結題),主要研究者。

獲獎及榮譽:

1.原核表達類病毒顆粒疫苗研究團隊,“求是傑出科技成就集體獎”,2015

2.乙型肝炎病毒新變異及臨床治療預測的研究,2015年廈門市科技進步一等獎。

3.創新人才推進計劃重點領域創新團隊,科技部,2013年。

4.無償獻血者隱匿性乙肝病毒感染檢測體系的建立及應用,2011年廈門市科技進步二等獎。